panther confirm preview earlier week
dx test materi off-set drive
revenu number pt move higher
quarter pre-announce revenu organ beat
origin estim mainli driven core dx vs mse
blood vs mse partial off-set breast health weak vs
mse facil restrict access begin late march note mdx
revenu includ dx revenu impli core dx growth
bp underli momentum acceler ou dx revenu
aid cervic cancer co-test germani viral load test africa
surgic vs mse underli momentum strong mid-
march driven new product core myosur strength howev elect
procedur deferr began occur late march expect
materi impact april discuss oper margin
modestli estim improv bp y/i ep miss
estim mainli driven higher cog vs mse non-
panther test develop major disclosur upgrad share holog
profil procedur exposur conclud signific valuat
disconnect present stock versu fundament valu detail
signific opportun present diagnost test dx math
monday profil panther opportun could look like
see today announc introduct aptima molecular
assay run panther gener disclosur line
expect initi research-use-onli test provid
manufactur capac scale per week start late may run
panther system us sensitivity/specif detail
disclos expect test highli accur line rna
qualit assay hcv see packag insert combin
addit reagent capac instal base workflow dynam
system meaning advanc test dynam
reconcil financi expect dx test referenc
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
combin panther panther fusion dx test could
contribut revenu consist prior view assum
sell panther fusion test manufactur
see remain reconcili follow assum holog
sell test june max capac per week plu ruo test
aggreg asp modestli per manag
commentari impli panther dx sale given
manufactur capac significantli re-alloc assum
cannib rate combin manufactur end user capac
net impli panther revenu
dx revenu pt growth state previous continu see
stock reflect scenario base bull case relat futur
npv valu dx test see one day durat matter
market reflect phase model posit
believ go perceiv dx exposur stori materi
posit off-set updat model reflect new diagnost
test contribut pleas see exhibit updat build assumpt
number move higher dx exclud dx
test manag expect april organ growth declin
surgic segment impact breast skelet commentari
point declin april continu see april trough month
across med-tech therefor forecast may/jun declin margin less
sever respect translat declin
ex dx test consist prior model
therefor remain unchang said reflect dx
financi contribut model seen exhibit includ
revenu point growth point
growth term recoveri continu expect acut impact
rel rapid recoveri next month see manag
commentari point return normal also align
recoveri model recal capit discuss
longer-d gradual recoveri given hospit profit
becom focu expect sever margin impact
although note compani implement variou initi salari cut
furlough etc control spend
diagnost thesi upgrad thesi base materi
debat shift import diagnost test see holog
action panther signific catalyst help solv countri
capac issu continu expect share react posit light
posit sentiment associ diagnost offset rais
price target base ebitda discount
price target base ebitda multipl turn discount larg
cap devic peer see discount warrant given oper slower growth
end-market limit top-line upsid said compani diagnost test
develop two molecular
diagnost test
potenti drive signic nancial
contribut next month
potenti given share gain key segment
breast dx nearli tap
see increas activ
necessari shift wagmr higher
drive multipl
consensu
view descript risk reward theme
off-set procedur weak
recoveri rapid efcient
alloc capit accret shift
wamgr msd region creat
sustain runway growth
accret augment share
segment dx test provid
meaning off-set near-term activ
necessari fundament shift growth
prole higher leverag limit
procedur weak prolong
dx test impact mute
deceler back region post-
share gain becom tap
breast dx ep growth mute msd
driven limit oper leverag
deploy creat dis-synergi
advers impact organ growth
diagnost test drive
revenu like continu
elev level quarter
share repurchas buy-back activ
drive point ep growth
china india
view explan region hierarchi
research highest favor quintil
upsid mdx
deploy capit enter faster growth
breast health dx segment growth rate
acceler
dx test impact mute via
procedur delay
peer effect cap organ
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
sale
sale
sale
sale
capac
capac
good sold
invest
treasuri
accumul comprehens
loss dispos properti equip
excess tax benefit relat equiti award
charg in-process d/writeoff
net chang work capit
purchas properti equip
dispos properti equip
busi acquisit net cash
net cash paid acquisit intang
proce sale intellectu properti
chg short-term debt
chg long-term debt
chang equiti net tax benefit
net decreas invest
tax benefit exercis non-qual option
effect exchang rate chang
begin period
end period
